European Network of Gynaecological Oncological Trial Groups

• NCT07218809

  Collaborator, Phase 3, Recruiting, 1,100 people, 20 Oct 2025

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  Collaborator, Phase 3, Recruiting, 1,023 people, 14 Oct 2025

• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  Collaborator, Phase 3, Recruiting, 1,630 people, 9 Oct 2025

• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  Collaborator, Phase 3, Recruiting, 600 people, 25 May 2025

• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  Collaborator, Phase 3, Recruiting, 770 people, 13 Feb 2025

• NCT06486441

  Collaborator, Phase 3, Active, not recruiting, 640 people, 3 Jul 2024

• NCT06132958

  Collaborator, Phase 3, Active, not recruiting, 710 people, 15 Nov 2023

• A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  Collaborator, Phase 3, Recruiting, 270 people, 10 Oct 2023

• NCT05872204

  Collaborator, Phase 2, Recruiting, 100 people, 24 May 2023

• NCT05870748

  Collaborator, Phase 2/3, Terminated, 600 people, 23 May 2023

• NCT05712941

  Collaborator, Phase 3, Withdrawn, 0 people, 6 Feb 2023

• NCT05173987

  Collaborator, Phase 3, Active, not recruiting, 280 people, 30 Dec 2021

• NCT05009082

  Collaborator, Phase 3, Recruiting, 970 people, 17 Aug 2021

• NCT04943627

  Collaborator, Phase 3, Withdrawn, 0 people, 29 Jun 2021

• NCT04931342

  Collaborator, Phase 2, Active, not recruiting, 176 people, 18 Jun 2021

• NCT04729608

  Collaborator, Phase 3, Terminated, 366 people, 28 Jan 2021

• NCT04634877

  Collaborator, Phase 3, Active, not recruiting, 990 people, 18 Nov 2020

• NCT04269200

  Collaborator, Phase 3, Active, not recruiting, 805 people, 13 Feb 2020

• NCT04221945

  Collaborator, Phase 3, Completed, 1,060 people, 9 Jan 2020

• NCT04209855

  Collaborator, Phase 3, Completed, 453 people, 24 Dec 2019

Sources: clinicaltrials.gov